XPO4

Across TCGA pan-cancer cohorts, XPO4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated XPO4 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher XPO4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated XPO4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where XPO4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.958	0.854	<.001	22	view →
HNSC	DFS	Tertile	II,III,IV	0.680	0.889	.011	19	view →
CCRCC	DFS	Tertile	All	1.000	0.534	.029	4	view →
LSCC	DFS	Median	III,IV	0.882	1.000	.039	2	view →
GBM	OS	Tertile	All	0.581	0.373	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

XPO4–LUAD (DFS)

Open the LUAD breakdown →